Molecular and Cellular Biology, January 2001, p. 148-155, Vol. 21, No. 1
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.1.148-155.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
IDI-IRCCS Biochemistry Lab, Department of Experimental Medicine, University Tor Vergata, Rome, Italy
Received 20 July 2000/Returned for modification 12 September 2000/Accepted 28 September 2000
| |
ABSTRACT |
|---|
|
|
|---|
Transglutaminase 2 (TGase 2), or tissue transglutaminase, catalyzes
either
-(
-glutamyl)lysine or
N1,N8-(
-glutamyl)spermidine
isopeptide bonds. TGase 2 expression has been associated with
apoptosis, and it has been proposed that its activation should lead to
the irreversible assembly of a cross-linked protein scaffold in dead
cells. Thus, TGase 2-catalyzed protein polymerization contributes to
the ultrastructural changes typical of dying apoptotic cells; it
stabilizes the integrity of the apoptotic cells, preventing the release
of harmful intracellular components into the extracellular space and,
consequently, inflammation and scar formation. In order to perform a
targeted disruption of the enzyme, we prepared a construct deleting
part of exons 5 and 6, containing the active site, and intron 5. Complete absence of TGase 2 was demonstrated by reverse
transcription-PCR and Western blot analysis. TGase activity measured on
liver and thymus extracts showed, however, a minimal residual activity
in TGase 2
/
mice. PCR analysis of mRNA extracted from
the same tissues demonstrated that at least TGase 1 (normally present
in the skin) is also expressed in these tissues and contributes to this
residual activity. TGase 2
/
mice showed no major
developmental abnormalities, and histological examination of the major
organs appeared normal. Induction of apoptosis ex vivo in TGase
2
/
thymocytes (by CD95, dexamethasone, etoposide, and
H2O2) and in vitro on TGase 2
/
mouse embryonal fibroblasts (by retinoids, UV, and
H2O2) showed no significant differences. A
reduction in cross-linked apoptotic bodies with a modestly increased
release of lactate dehydrogenase has been detected in some cases.
Together our results show that TGase 2 is not a crucial component of
the main pathway of the apoptotic program. It is possible that the
residual enzymatic activity, due to TGase 1 or redundancy of other
still-unidentified TGases, can compensate for the lack of TGase 2.
| |
INTRODUCTION |
|---|
|
|
|---|
Transglutaminase 2 (TGase 2;
also called tissue transglutaminase or TG C) belongs to the
transglutaminase (EC 2.3.2.13) family, which includes
intracellular and extracellular enzymes catalyzing
Ca2+-dependent reactions resulting in the formation of
-(
-glutamyl)lysine cross-links and/or in the covalent
incorporation of di- and polyamines and histamine (25,
26). The establishment of these covalent cross-links leads to
the posttranslational modification and, in many instances, the
oligomerization of substrate proteins. The resulting protein polymers
are resistant to breakage and chemical attack and can release
polypeptides only through the proteolytic degradation of protein
chains. At least seven distinct types of TGases in mammals have been
characterized: TGase 1 (or TG K), TGase 2, TGase 3 (or TG E),
TGase X, coagulation factor XIII, band 4.2., and prostate TGase.
At least four transglutaminases (TGases 1, 2, 3, and X) are
expressed and synthesized during terminal differentiation and death of
human epidermal keratinocytes (44, 45), where they
contribute to the formation of the cornified envelope.
The TGase 2 gene is constitutively expressed both during development
(29, 48) and in adult tissues (for a review, see reference
36). In both cases a tight correlation between TGase 2 expression and occurrence of apoptosis has been found. This includes,
for example, interdigital web formation (29), implantation of the embryo in utero (35), and mammary gland regression
(31, 46). In addition, the presence and activity of the
enzyme have been shown to increase in cells undergoing apoptosis in
several models (2, 9, 10, 21, 23-25, 32-34, 37, 40).
Indeed, during apoptosis de novo transcription of the TGase 2 gene is induced by several factors (e.g., retinoic acid [RA], prostaglandin E2, interleukin 6, and tumor growth factor
). Moreover, in addition to transcriptional regulation (24, 28, 41), TGase 2 can also be modulated posttranscriptionally (1, 23, 50) during apoptosis. TGase 2 activation leads to the assembly of intracellular cross-linked protein polymers, which irreversibly modifies cell organization, contributing to the wide ultrastructural changes occurring in cells undergoing apoptosis (9, 10, 39). This extensive TGase 2-dependent protein polymerization stabilizes apoptotic
cells before their clearance by phagocytosis, thus contributing to the
prevention of inflammation in the surrounding tissues
(39).
In addition to its cross-linking activity, TGase 2 acts as the G
h
subunit, associated with the 50-kDa
subunit (G
h), of the
GTP-binding protein (Gh) in a ternary complex associated with the rat
liver
1-adrenergic receptor (30). Thus, TGase 2-G
h is a multifunctional protein, which by binding GTP in a G
h-GTP complex can modulate receptor-stimulated phospholipase C activation.
In order to clarify the role of TGase 2 in apoptosis we have generated mice lacking TGase 2 by homologous recombination techniques. Our results, however, show that the disruption of TGase 2 does not produce a major phenotype and that apoptosis still occurs normally in the absence of TGase 2.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Reagents. Ham's F-12 and minimal essential media were from Gibco (Berlin, Germany), and fetal calf serum was from HyClone (Oud-Beijerland, The Netherlands). HEPES, bovine serum albumin (BSA), RNase A, propidium iodide (PI), Triton X-100, RA, N,N'-dimethylcasein, and putrescine were obtained from Sigma Chemical (St. Louis, Mo.). The mouse monoclonal anti-TGase 2 antibodies (clone CUB 7402 and clone CUB 7402+TG100) were purchased from Neo-Markers (Union City, Calif.). All electrophoresis reagents and secondary antibodies were from Bio-Rad (Richmond, Calif.) [3H]putrescine was obtained from Amersham (Arlington Heights, Ill.).
Generation of TGase 2-deficient mice.
A genomic clone
containing the genomic sequence 3' of exon 5 was isolated by screening
a 129/SvJ mouse genomic library (Stratagene, La Jolla, Calif.). The
targeting vector (Fig. 1A) was
constructed by cloning an ~4-kb EcoRV/BamHI
fragment of this clone, containing the sequence from intron 6 to exon
9, into the pPNT vector (49) 3' of the neomycin resistance
gene between the XbaI and BamHI unique sites. An
~2-kb fragment containing intron 3 was generated by PCR using primers
designed on the basis of the sequence of exons 4 and 5. This fragment
was cloned into the XhoI site of the pPNT vector 5' of the
neomycin resistance gene. This construct deletes 1.2 kb containing part
of exon 5, intron 5, exon 6, and a small piece of intron 6 up to the
EcoRV site.
|
Cell cultures. Mouse embryonic fibroblasts (MEFs) and thymocytes were grown in a 1:1 mixture of minimal essential medium and Ham's F-12 medium supplemented with 10% heat-inactivated fetal calf serum, 1.2 g of sodium bicarbonate per liter, and 15 mM HEPES at 37°C with 5% CO2 in a humidified atmosphere.
Western blotting. Livers were homogenized in 3 ml of cold lysis buffer containing 100 mM Tris-HCl (pH 7.4), 10 mM KCl, 2 mM MgCl2, 0.1% Triton X-100, 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride. They were then centrifuged, and the protein content of the supernatants was determined using the Bradford method (Bio-Rad). Proteins were normalized to 30 µg/lane, separated on sodium dodecyl sulfate (SDS)-12% polyacrylamide gels, and blotted onto nitrocellulose sheets. Filters were washed twice with phosphate-buffered saline (PBS) containing 0.1% Tween 20 before blocking nonspecific binding overnight with 10% nonfat milk and 5% BSA dissolved in PBS-0.1% Tween 20. The TGase 2 antigen was detected by incubation for 2 h with a 1:1 mixture of mouse monoclonal anti-TGase 2 antibodies (1:300 in PBS-0.1% Tween 20). Nitrocellulose filters were washed five times, and detection was performed by horseradish peroxidase-conjugated goat anti-mouse monoclonal antibody (1:2,500 in PBS-0.1% Tween 20 with 10% milk and 5% BSA) for 1 h at room temperature, using the ECL method (Amersham).
Enzyme assay. TGase activity was determined by measuring the incorporation of [3H]putrescine into N,N'-dimethylcasein (22, 26). The reaction mixture contained 150 mM Tris-HCl buffer (pH 8.3), 90 mM NaCl, 10 mM dithiothreitol, 15 mM CaCl2, 12.5 mg of N,N'-dimethylcasein/ml, and 0.2 mM putrescine containing 1 µCi of [3H]putrescine. Proteins from different tissue and cellular extracts (0.1 to 0.3 mg) were incubated with the reaction mixture in a final volume of 150 µl at 37°C. After 20 min of incubation, the reaction was stopped by spotting 100-µl quadruplicate aliquots onto Whatman 3MM filter paper. Unbound [3H]putrescine was removed by washing with large volumes of 15, 10, and 5% trichloroacetic acid and absolute ethanol. Filters were then air dried and the radioactivity was measured by liquid scintillation counting.
PCR analysis of TGases 2 and 1. Total RNA was extracted from mouse livers, using the RNeasy minikit from Qiagen (Crawley, United Kingdom). Reverse transcription (RT)-PCRs were performed with the RT-PCR One Step System (Life Technologies, Paisley, United Kingdom), using 100 ng of total RNA, according to the manufacturer's instructions. The primers used for the amplification of TGase 2 were TG30 (5'GACAACAACTATGGGGATGGT3') and TG9B (5'ATCATCTCGCTCTTGTTCGTC3'). The primers used for the amplification of TGase 1 were MTG1F (5'ACCACCACAGTGCTCCGATG3') and MTG1R (CCACACGTGGAAGTTCCAAAC3'). The following PCR program was used in all cases: 42°C for 30 min and 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 57°C for 30 s, and 70°C for 30 s. PCR products were resolved on a 1.6% agarose gel and stained with ethidium bromide.
Determination of cell death.
To estimate DNA fragmentation,
a mixture of floating cells and cells mechanically recovered from
flasks, which had been subjected to different treatments, were
collected at 800 × g for 10 min and fixed with a 1:1
solution of PBS and methanol-acetone (4:1, vol/vol) at
20°C. The
cell cycle was evaluated by flow cytometry using PI staining (40 mg/ml)
(22) in the presence of 13 kU of RNase A per ml (20 min of
incubation at 37°C) on a FACS-Calibur flow cytometer (Becton
Dickinson, San Jose, Calif.). Cells were excited at 488 nm using a
15-mW argon laser, and the fluorescence was monitored at 578 nm at a
rate of 150 to 300 events/s. Ten thousand events were evaluated using
the Cell Quest program (Becton Dickinson). Electronic gating
(FSC-a/vs/FSC-h) was used, when appropriate, to eliminate cell aggregates.
LDH release. For measurement of lactate dehydrogenase (LDH) levels, a kit was used according to the manufacturer's instructions (Sigma Chemical). Briefly, the cell culture supernatant was incubated with pyruvate and NADH, and the LDH activity was determined photometrically at 340 nm.
Quantification of cross-linked apoptotic bodies.
Cross-linked apoptotic bodies were estimated on cells cultured in
175-cm2 flasks, as previously described (26).
Cells floating in the culture medium were collected by centrifugation
at 800 × g for 10 min and pooled with the cells
mechanically recovered from flasks. After being washed in PBS, cells
were suspended in 1 ml of lysis buffer (10 mM KCl, 2 mM
MgCl2, and 0.5% Triton X-100 in 10 mM Tris-HCl, pH 7.4)
containing 1 mM phenylmethylsulfonyl fluoride and 2 mM iodoacetamide.
After centrifugation the pellet was washed in lysis buffer, suspended
in a 2% sodium dodecyl sulfate solution containing 5%
-mercaptoethanol, and boiled, and the number of detergent-insoluble
apoptotic bodies was scored using a phase-contrast microscope (Diaphot;
Nikon) and normalized to milligrams of protein.
| |
RESULTS |
|---|
|
|
|---|
Generation of TGase 2-deficient mice. The TGase 2 gene was disrupted by homologous recombination. The targeting vector deletes 1,200 bp of the TGase gene from exon 5 to intron 6. This deletion includes exon 6, which contains the active site. The loss of the catalytic site abolishes the protein cross-linking activity of TGase 2, consequently removing its presumed role in the formation of the apoptotic body. Figure 1 shows the targeting vector and the screening strategy.
TGase 2
/
mice show no clear phenotypic abnormality
(macroscopic or microscopic); they develop normally and are capable of
reproducing at the expected frequency.
In order to confirm that no TGase 2 protein is produced in TGase
2-deficient mice, we performed Western blot analysis on liver, thymus,
brain, and erythrocyte extracts from wild-type animals (TGase
2+/+) and from TGase 2
/
mice. Our results
show the absence of TGase 2 protein in the
/
animals (Fig.
2A shows liver extracts). However,
measurement of TGase activity (Fig. 2B) in different tissues extracted
from TGase 2
/
animals showed that some residual TGase
enzyme activity was still present. Indeed, while erythrocytes showed a
reduction in activity close to 100%, thymocytes showed the highest
level of residual TGase activity, which is quite significant compared
with the activity of TGase 2+/+ animals. RT-PCR of RNA
extracted from thymus tissues of both +/+ and
/
animals showed that
no transcript for TGase 2 was present in
/
animals (Fig. 2C).
|
/
and +/+ animals. This should account
for the residual TGase enzymatic activity.
TGase 2
/
thymocytes and MEFs show normal induction
of apoptosis.
Since a large number of reports suggest a role for
TGase 2 in apoptosis, including in vivo in the thymus
(47), we studied apoptosis induced ex vivo in mouse
thymocytes and in vitro in MEFs.
/
animals
with any of the treatments.
|
/
MEFs were treated in vitro with H2O2
(Fig. 4A), RA (Fig. 4B), or UV (Fig. 4C).
Treatment of +/+ MEFs with RA and UV resulted in an increase in TGase
activity;
/
MEFs had a much lower basal activity that increased
with UV and H2O2 treatment, while RA treatment
resulted in a decrease of TGase activity (Fig. 4D). Since TGase 1 is
negatively regulated by retinoids, while TGase 2 is upregulated
(50), these results are in keeping with the evidence that
the minimal residual activity observed in MEFs is due to TGase 1 (Fig.
4D). Indeed, as for thymocytes, mRNA for TGase 1 was also detected in
MEFs by RT-PCR (data not shown).
|
Cross-linked apoptotic body formation is present in TGase
2
/
mice.
It has been consistently suggested that
TGase 2 induction during apoptosis results in the formation of
cross-linked insoluble apoptotic bodies. In order to investigate the
possibility that the formation of cross-linked apoptotic bodies is
impaired in TGase 2
/
mice, we measured the number of
insoluble apoptotic bodies in control or RA-, UV-, and
H2O2-treated MEFs. Figure
5A shows that apoptotic bodies also
formed in TGase 2
/
cells, even though the number of
cross-linked apoptotic bodies was significantly reduced in UV- and
H2O2-treated
/
MEFs.
|
/
MEFs after induction of apoptosis with UV, RA,
and H2O2. Figure 5B shows that LDH release was
only moderately increased (not statistically significant) in +/+ versus
/
MEFs. Treatment with UV, with which some necrosis was expected, showed a significant increase in LDH release in both +/+ and
/
cells. Therefore, our results are consistent with an essentially normal
induction of apoptosis.
| |
DISCUSSION |
|---|
|
|
|---|
We have generated TGase 2-deficient mice through homologous
recombination techniques. No TGase 2 was detectable in these mice by
RT-PCR or Western blotting. The mice were viable and fertile and showed
no developmental abnormalities. Apoptosis induced with different agents
in both fibroblasts and thymocytes is normal. The reduction in
enzymatic activity in
/
mice showed only a minor effect on both
cross-linked apoptotic body formation (Fig. 5A) and LDH release
(Fig. 5B), with no major consequences for the mice. Although we cannot
exclude the possibility that TGase 2 deficiency may play a role in
pathological situations (11, 38), aged mice (up to 20 months of age) do not show abnormalities such as cancer development and
generation of autoimmunity (data not shown). It might be necessary to
cross the mice into a more permissive genetic background in order to
reveal an overt phenotype.
Deletion of various genes involved in apoptosis does not always
produce an evident phenotype. Mice with deleted caspases 1, 2, 6, and
11 do not show evident developmental abnormalities (51), while in other cases a very specific or minimal phenotype is observed. Disruptions of other genes produce a phenotype only when animals are
stressed with specific inducers requiring that protein, namely, radiation on p53
/
(8) or liposaccharides
on caspase 1
/
(16, 18) cells. Even though
the accredited model for apoptosis indicates the requirement
for the apoptosome and in particular for apaf-1 and caspases 3 and 9 (for a review, see references 6 and
17), the knockout of the genes for these proteins
shows that thymocytes are still able to undergo apoptosis (for
a review, see references 5 and
51). This has elicited various explanations, including the existence of additional unknown pathways or compensation mechanisms.
Similarly, there are different possible interpretations for the lack of phenotype in TGase 2 animals: (i) TGase 2 is not involved in apoptosis; (ii) it is not involved in the central, essential apoptotic machinery, but it is part of a regulatory or side pathway elicited only by specific inducers or only in specific tissues; or (iii) there is redundancy in the system.
The lack of effect on apoptosis of targeted disruption of the
TGase 2 gene is in apparent contrast to previous evidence in favor of a
role for TGase 2 in the apoptotic program. Indeed, it has been
shown previously that transfection of an antisense TGase 2 construct
into cell lines confers resistance to apoptosis induction,
while sense transfectants show enhanced spontaneous apoptosis
(22). There are several reasons for this disparity. First,
not all models of apoptosis require TGase 2. For example, CD95
ligation elicits apoptosis independently of the steady-state levels of TGase 2 protein (3); correspondingly, there is
no change in TGase enzymatic activity during CD95-induced
apoptosis (3). Second, other TGases may assume the
protein cross-linking role of TGase 2. Indeed, the TGase
2
/
mice showed different degrees of TGase enzymatic
activity in different tissues. Our data show the presence of TGase 1 in
both +/+ and
/
mice. Recently, TGase 1 has been shown to exist in tissues different from the skin, namely, in the central nervous system
(15). Furthermore, the TGase activity levels in
/
thymocytes is inhibited by GTP, a property of TGase X (E. Candi, G. Melino, et al., unpublished observation), suggesting its expression in lymphoid tissue. Therefore, the possibility that other TGases, and
particularly TGase 1, can compensate for TGase 2 loss cannot be
excluded. TGases show very different biochemical properties, such as
kcat/Km ratio, residue
preference, and yield (26). Therefore, it is unlikely that
there is a perfect compensation among distinct TGases. In fact, TGase 1 knockout animals show a lethal phenotype, despite the presence of four
distinct TGases in the skin (20). However, point mutations
for TGase 1 in humans, with complete loss of TGase enzymatic activity
(4), are compatible with life but cause a skin disease
known as lamellar ichthyosis (12, 42), suggesting a
different degree of compensation in humans.
Despite the large body of data suggesting an involvement of TGase 2 in
apoptosis, its precise role in this process is not evident from
the present gene disruption study. While the TGase 2
/
animals could be used to study other functions of the enzyme, particularly by further crossbreeding to evaluate its contribution in
pathologies such as celiac (7, 27) and Huntington
(13, 14, 19, 43) diseases, clarification of the importance
of TGase 2 in apoptosis may well require the generation of
animals deficient in multiple TGases.
| |
ACKNOWLEDGMENTS |
|---|
We thank Mauro Piacentini, Gennaro Ciliberto, and Richard A. Knight for generous support, critical discussions, and helpful suggestions. This work could not have been completed without the generous help of Francesca Bernassola, Eleonora Candi, Marco Corazzari, Daniela Barcaroli, and Marco Ranalli. We thank Giuseppe Bertini, Giancarlo Cortese, and Pierino Piccoli (S.S.D. SAFU, Instituto Fisioterapici Ospedalieri, Rome, Italy) for technical assistance and mouse husbandry.
The work was partially supported by grants from MURST, MinSan, Associazione Neuroblastoma, AIRC, Telethon (E 872 and E 1257), and EU (QLG1-1999-00739).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: IDI-IRCCS, Biochemistry Lab, c/o Dep. Experimental Medicine, D26/F153, University of Rome Tor Vergata, Via Tor Vergata 135, 00133 Rome, Italy. Phone: 39 6 20427299. Fax: 39 6 20427290. E-mail: gerry.melino{at}uniroma2.it.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Achyuthan, K. E., and C. S. Greenberg.
1987.
Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity.
J. Biol. Chem.
262:1901-1906 |
| 2. |
Amendola, A.,
M. L. Gougeon,
F. Poccia,
A. Bondurand,
L. Fesus, and M. Piacentini.
1996.
Induction of "tissue" transglutaminase in HIV-pathogenesis: evidence for high rate of apoptosis of CD4+ T lymphocytes and accessory cells in lymphoid tissues.
Proc. Natl. Acad. Sci. USA
93:11057-11062 |
| 3. | Bernassola, F., C. Scheurpflug, I. Herr, P. H. Krammer, K. M. Debatin, and G. Melino. 1999. Induction of apoptosis by IFNgamma in human neuroblastoma cell lines through the CD95/CD95L autocrine circuit. Cell Death Differ. 6:652-660[CrossRef][Medline]. |
| 4. |
Candi, E.,
G. Melino,
A. Lahm,
R. Ceci,
A. Rossi,
I.-G. Kim,
B. Ciani, and P. M. Steinert.
1998.
Transglutaminase 1 mutations in lamellar ichthyosis.
J. Biol. Chem.
273:13693-13702 |
| 5. | Cecconi, F. 1999. Apaf1 and the apoptotic machinery. Cell Death Differ. 6:1087-1098[CrossRef][Medline]. |
| 6. | De Laurenzi, V., and G. Melino. 2000. Apoptosis. The little devil of death. Nature 406:135-136[CrossRef][Medline]. |
| 7. | Dieterich, W., T. Ehnis, M. Bauer, P. Donner, U. Volta, E. O. Riecken, and D. Schuppan. 1997. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3:797-801[CrossRef][Medline]. |
| 8. | Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221[CrossRef][Medline]. |
| 9. | Fesus, L., V. Thomazy, F. Autuori, M. P. Ceru', E. Tarcsa, and M. Piacentini. 1989. Apoptotic hepatocytes become insoluble in detergents and chaotropic agents as a result of transglutaminase action. FEBS Lett. 245:150-154[CrossRef][Medline]. |
| 10. | Fesus, L., P. J. A. Davies, and M. Piacentini. 1991. Apoptosis: molecular mechanisms in programmed cell death. Eur. J. Cell Biol. 56:170-177[Medline]. |
| 11. | Hettasch, J. M., N. Bandarenko, J. L. Burchette, T. S. Lai, J. R. Marks, Z. A. Haroon, K. Peters, M. W. Dewhirst, J. D. Iglehart, and C. S. Greenberg. 1996. Tissue transglutaminase expression in human breast cancer. Lab. Investig. 75:637-645[Medline]. |
| 12. |
Huber, M.,
I. Rettler,
K. Bernasconi,
E. Frenk,
S. P. Lavrijsen,
M. Ponec,
A. Bon,
S. Lautenschlager,
D. F. Schorderet, and D. Hohl.
1995.
Mutations of keratinocyte transglutaminase in lamellar ichthyosis.
Science
267:525-528 |
| 13. | Igarashi, S., R. Koide, T. Shimohata, M. Yamada, Y. Hayashi, H. Takano, H. Date, M. Oyake, T. Sato, A. Sato, S. Egawa, T. Ikeuchi, H. Tanaka, R. Nakano, K. Tanaka, I. Hozumi, T. Inuzuka, H. Takahashi, and S. Tsuji. 1998. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat. Genet. 18:111-117[CrossRef][Medline]. |
| 14. | Kahlem, P., H. Green, and P. Djian. 1998. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1:595-601[CrossRef][Medline]. |
| 15. |
Kim, S. Y.,
P. Grant,
J. H. Lee,
H. C. Pant, and P. M. Steinert.
1999.
Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease.
J. Biol. Chem.
274:30715-30721 |
| 16. | Kuida, K., J. A. Lippke, G. Ku, M. W. Harding, D. J. Livingstone, M. S.-S. Su, and R. A. Flavell. 1995. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 281:2000-2002. |
| 17. | Kumar, S. 1999. Mechanisms mediating caspase activation in cell death. Cell Death Differ. 6:1060-1066[CrossRef][Medline]. |
| 18. | Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnstone, J. McDowell, M. Paskind, L. Rodman, J. Salfeld, E. Townes, D. Tracey, S. Wardwell, F.-Y. Wei, W. W. Wong, R. Kamen, and T. Seshadri. 1995. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL beta and resistant to endotoxic shock. Cell 80:401-411[CrossRef][Medline]. |
| 19. | Lorand, L. 1998. DRPLA aggregation and transglutaminase, revisited. Nat. Genet. 20:231[CrossRef][Medline]. |
| 20. |
Matsuki, M.,
F. Yamashita,
A. Ishida-Yamamoto,
K. Yamada,
C. Kinoshita,
S. Fushiki,
E. Ueda,
Y. Morishima,
K. Tabata,
H. Yasuno,
M. Hashida,
H. Iizuka,
M. Ikawa,
M. Okabe,
G. Kondoh,
T. Kinoshita,
J. Takeda, and K. Yamanishi.
1998.
Defective stratum corneum and early neonatal death in mice lacking the gene for transglutaminase 1 (keratinocyte transglutaminase).
Proc. Natl. Acad. Sci. USA
95:1044-1049 |
| 21. | Melino, G., M. G. Farrace, M. P. Ceru', and M. Piacentini. 1988. Correlation between transglutaminase activity and polyamine levels in human neuroblastoma cells. Effect of retinoic acid and alpha-difluoromethylornithine. Exp. Cell Res. 179:429-445[CrossRef][Medline]. |
| 22. |
Melino, G.,
M. Annicchiarico-Petruzzelli,
L. Piredda,
E. Candi,
V. Gentile,
P. J. A. Davies, and M. Piacentini.
1994.
Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells.
Mol. Cell. Biol.
14:6584-6596 |
| 23. | Melino, G., F. Bernassola, M. T. Corasaniti, R. A. Knight, G. Nistico, and A. Finazzi-Agro. 1997. S-nitrosylation regulates apoptosis. Nature 388:432-433[CrossRef][Medline]. |
| 24. | Melino, G., M. Draoui, M. Piacentini, L. Bellincampi, F. Bernassola, U. Reichert, and P. Cohen. 1997. Retinoic acid receptors a and g mediate tissue-transglutaminase induction in human neuroblastoma cells undergoing apoptosis. Exp. Cell Res. 255:55-61. |
| 25. | Melino, G., and M. Piacentini. 1998. Tissue transglutaminase in apoptosis: a downstream or a multifunctional upstream effector? FEBS Lett. 430:59-63[CrossRef][Medline]. |
| 26. | Melino, G., E. Candi, and P. M. Steinert. 2000. Assay for transglutaminases in cell death. Methods Enzymol 322:433-472[Medline]. |
| 27. | Molberg, O., S. N. Mcadam, R. Korner, H. Quarsten, C. Kristiansen, L. Madsen, L. Fugger, H. Scott, O. Noren, P. Roepstorff, K. E. Lundin, H. Sjostrom, and L. M. Sollid. 1998. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat. Med. 4:713-717[CrossRef][Medline]. |
| 28. |
Nagy, L.,
M. Saydak,
N. Shipley,
S. Lu,
J. P. Basilion,
Z. H. Yan,
P. Syka,
R. Chandraratna,
R. Heyman, and P. J. A. Davies.
1996.
Identification and characterization of a versatile retinoid response element (RARE/RXRE) in the promoter of the mouse tissue transglutaminase gene.
J. Biol. Chem.
271:4355-4365 |
| 29. | Nagy, L., V. A. Thomazy, M. M. Saydak, J. P. Stein, and P. J. A. Davies. 1997. The promoter of mouse tissue transglutaminase gene directs tissue-specific, retinoid-regulated and apoptosis-linked expression. Cell Death Differ. 4:534-547. |
| 30. |
Nakaoka, H.,
D. M. Perez,
K. J. Baek,
T. Das,
A. Husain,
K. Misono,
M. Im, and R. M. Graham.
1994.
Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function.
Science
264:1593-1596 |
| 31. | Nemes, Z., Jr., R. R. Friis, D. Aeschlimann, S. Saurer, M. Paulsson, and L. Fesus. 1996. Expression and activation of tissue transglutaminase in apoptotic cells of involuting rodent mammary tissue. Eur. J. Cell Biol. 70:125-133[Medline]. |
| 32. | Piacentini, M., L. Fesus, M. G. Farrace, L. Ghibelli, L. Piredda, and G. Melino. 1991. The expression of "tissue" transglutaminase in two human cancer cell lines is related with the programmed cell death (apoptosis). Eur. J. Cell Biol. 54:246-254[Medline]. |
| 33. | Piacentini, M., M. Annicchiarico-Petruzzelli, S. Oliverio, L. Piredda, J. L. Biedler, and G. Melino. 1992. Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int. J. Cancer 52:271-278[Medline]. |
| 34. | Piacentini, M., L. Fesus, and G. Melino. 1993. Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells. FEBS Lett. 320:150-154[CrossRef][Medline]. |
| 35. | Piacentini, M., and F. Autuori. 1994. Immunohistochemical localization of tissue transglutaminase and Bcl-2 in rat uterine tissues during embryo implantation and post-partum involution. Differentiation 57:51-61[CrossRef][Medline]. |
| 36. | Piacentini, M. 1995. Tissue transglutaminase: a candidate effector element of physiological cell death. Curr. Top. Microbiol. Immunol. 200:163-176[Medline]. |
| 37. | Piacentini, M., L. Piredda, D. Starace, M. Annicchiarico-Petruzzelli, M. Mattel, S. Oliverio, M. G. Farrace, and G. Melino. 1996. Differential growth properties of S- and N-type human neuroblastoma cell variants transplanted into SCID mice: correlation with apoptosis and effect of ethanol. J. Pathol. 180:415-422[CrossRef][Medline]. |
| 38. | Piacentini, M., and V. Colizzi. 1999. Tissue transglutaminase: apoptosis versus autoimmunity. Immunol. Today 20:130-134[CrossRef][Medline]. |
| 39. | Piredda, L., A. Amendola, V. Colizzi, P. J. A. Davies, M. G. Farrace, M. Fraziano, V. Gentile, I. Uray, M. Piacentini, and L. Fesus. 1997. Lack of "tissue" transglutaminase protein cross-linking leads to leakage of macromolecules from dying cells: relationship to development of autoimmunity in MRLIpr/Ipr mice. Cell Death Differ. 4:463-472. |
| 40. |
Piredda, L.,
M. G. Farrace,
M. Lo Bello,
W. Malorni,
G. Melino,
R. Petruzzelli, and M. Piacentini.
1999.
Identification of 'tissue' transglutaminase binding proteins in neural cells committed to apoptosis.
FASEB J.
13:355-364 |
| 41. |
Ritter, S. J., and P. J. Davies.
1998.
Identification of a transforming growth factor-beta1/bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter.
J. Biol. Chem.
273:12798-12806 |
| 42. | Russell, L. J., J. J. DiGiovanna, G. R. Rogers, P. M. Steinert, N. Hashem, J. G. Compton, and S. J. Bale. 1995. Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat. Genet. 9:279-283[CrossRef][Medline]. |
| 43. | Saudou, F., S. Finkbeiner, D. Devys, and M. E. Greenberg. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66[CrossRef][Medline]. |
| 44. | Steinert, P. M. 1995. A model for the hierarchical structure of the human epidermal cornified cell envelope. Cell Death Differ. 2:33-40[Medline]. |
| 45. | Steinert, P. M., E. Candi, E. Tarcsa, L. N. Marekov, M. Sette, M. Paci, B. Ciani, P. Guerrieri, and G. Melino. 1999. Transglutaminase crosslinking and structural studies of the human small proline rich 3 protein. Cell Death Differ. 6:916-930[CrossRef][Medline]. |
| 46. | Strange, R., F. Li, S. Saurer, A. Bukhard, and R. R. Friis. 1992. Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 115:49-58[Abstract]. |
| 47. | Szondy, Z., P. Molnar, Z. Nemes, M. Boyiardzis, N. Kedei, R. Toth, and L. Fesus. 1997. Differential expression of transglutaminase during in vivo apoptosis of thymocytes induced via distinct signalling pathways. FEBS Lett. 404:307-313[CrossRef][Medline]. |
| 48. | Thomazy, V. A., and P. J. Davies. 1999. Expression of tissue transglutaminase in the developing chicken limb is associated both with apoptosis and endochondral ossification. Cell Death Differ. 6:146-154[CrossRef][Medline]. |
| 49. | Tybulewicz, V. L., C. E. Crawford, P. K. Jackson, R. T. Bronson, and R. C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163[CrossRef][Medline]. |
| 50. |
Zhang, L. X.,
K. J. Mills,
M. I. Dawson,
S. J. Collins, and A. M. Jetten.
1995.
Evidence for the involvement of retinoic acid receptor RAR alpha-dependent signaling pathway in the induction of tissue transglutaminase and apoptosis by retinoids.
J. Biol. Chem.
270:6022-6029 |
| 51. | Zheng, T. S., S. Hunot, K. Kuida, and R. A. Flavell. 1999. Caspase knockouts: matters of life and death. Cell Death Differ. 6:1043-1053[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|